Department of Ophthalmology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, Ibaraki, 305-8575, Japan.
Eye (Lond). 2022 Feb;36(2):457-462. doi: 10.1038/s41433-021-01452-x. Epub 2021 Mar 11.
To quantify stereopsis and other visual functions in patients with unilateral branch retinal vein occlusion (BRVO) and to investigate vision-related parameters that affect stereopsis.
Prospective observational study.
Forty-five patients undergoing intravitreal ranibizumab (IVR) treatment for unilateral BRVO.
We examined stereopsis using the Titmus stereo test (TST) and TNO stereotest (TNO), best corrected visual acuity (BCVA), letter contrast sensitivity, severity of metamorphopsia and degree of aniseikonia before and 6 months after IVR.
Visual functions that affect stereopsis.
Baseline stereopsis in patients with BRVO was 2.7 ± 0.6 (range, 1.6-3.5) in the TST and 2.8 ± 0.5 (range, 1.8-3.3) in TNO. TST and TNO scores were significantly correlated with BCVA and letter contrast sensitivity at baseline (P < 0.001) but not with other visual functions. IVR treatment significantly improved stereopsis, BCVA, and letter contrast sensitivity. After treatment, TST scores were significantly correlated with BCVA (P < 0.001), letter contrast sensitivity (P < 0.001), and aniseikonia (P < 0.01). TNO scores were significantly correlated with BCVA (P < 0.01) and letter contrast sensitivity (P < 0.01). TST and TNO scores after treatment were significantly correlated with BCVA at baseline (P < 0.01 for both).
Deterioration of stereopsis in patients with BRVO was associated with changes in visual acuity and contrast sensitivity after treatment. Initial visual acuity is a prognostic factor for posttreatment stereopsis.
定量分析单侧视网膜分支静脉阻塞(BRVO)患者的立体视功能,并探讨影响立体视的相关视功能参数。
前瞻性观察性研究。
45 例接受玻璃体内雷珠单抗(IVR)治疗的单侧 BRVO 患者。
我们使用Titmus 立体视测试(TST)和 TNO 立体测试(TNO)、最佳矫正视力(BCVA)、字母对比度敏感度、变形觉严重程度和不等像程度来评估立体视,并在 IVR 治疗前后 6 个月进行评估。
影响立体视的视觉功能。
BRVO 患者的基线立体视敏度在 TST 中为 2.7 ± 0.6(范围,1.6-3.5),在 TNO 中为 2.8 ± 0.5(范围,1.8-3.3)。TST 和 TNO 评分与基线时的 BCVA 和字母对比度敏感度显著相关(P < 0.001),但与其他视觉功能无关。IVR 治疗显著改善了立体视、BCVA 和字母对比度敏感度。治疗后,TST 评分与 BCVA(P < 0.001)、字母对比度敏感度(P < 0.001)和不等像(P < 0.01)显著相关。TNO 评分与 BCVA(P < 0.01)和字母对比度敏感度(P < 0.01)显著相关。治疗后 TST 和 TNO 评分与基线时的 BCVA 显著相关(均 P < 0.01)。
BRVO 患者立体视功能的恶化与治疗后视力和对比敏感度的变化有关。初始视力是治疗后立体视的预后因素。